TP53 and cancer: This finding could potentially have bearing on the suitability of TIP60 as a target for cancer therapeutics, as the TP53 gene is mutated in 42% of cancers [71], and CDKN2A, encoding INK4A and ARF, is mutated in 3.6% in a pan-cancer study [71] and in up to 78% in specific types of pediatric leukemia [72].